| 28.24 0 (0%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Intersect ENT, Inc. is a medical technology firm focused on ear, nose, and throat (ENT) solutions, operating within the United States. Its product portfolio includes: PROPEL, PROPEL Mini, and PROPEL Contour: These are steroid-eluting implants. PROPEL is designed to maintain the patency of surgically enlarged sinuses, while PROPEL Mini targets patients undergoing frontal sinus procedures. PROPEL Contour specifically addresses the frontal and maxillary sinus ostia, or passages, within the dependent sinuses. SINUVA: Another steroid-releasing implant, intended for patient care in a clinical office environment. VENSURE Navigable and Stand-alone balloon: A sterile, single-use balloon device that facilitates access to and treatment of the frontal, sphenoid, and maxillary ostia in adult patients via a trans-nasal method. CUBE Navigation System: A digital guidance system offering high-accuracy navigation for ENT and associated skull-base surgical interventions. The company, originally established as Sinexus, Inc. in 2003, rebranded to Intersect ENT, Inc. in November 2009. Its corporate headquarters are located in Menlo Park, California.
Wed, 24 Dec 2025
Google drops $4.75bn on data center and energy firm Intersect - IT Pro
Mon, 22 Dec 2025
Google Is Spending Over $4 Billion on a Data Center Company - Gizmodo
Fri, 13 May 2022
Medtronic completes Intersect ENT acquisition - MassDevice
Wed, 26 Jan 2022
Ahead by more than a nose: Intersect study shows lower health care usage with sinus implant - BioWorld News
Thu, 28 Oct 2021
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe - Business Wire
Fri, 06 Aug 2021
Medtronic to Acquire Intersect ENT - Aug 6, 2021 - Medtronic
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|